Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ReProLine
- 12 Sep 2017 Results (n=446) assessing safety and efficacy, presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Status changed from recruiting to completed, presented at the 42nd European Society for Medical Oncology Congress.
- 23 Mar 2015 New trial record